Clinical Trial Update: Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial from AbbVie tests ABBV-637 alone or in combination with intravenous docetaxel or osimertinib in adults with relapsed/refractory soli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• ABBV-637
• DOCETAXEL (DOCETAXEL)
• Osimertinib (osimertinib)

Snippet

Sponsor: AbbVie | Conditions: Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Status: ACTIVE_NOT_RECRUITING